prikaz prve stranice dokumenta Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
  Preuzmi
PDF 425.35 KB
Znanstveni rad - Izvorni znanstveni rad
Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
Journal of Neuroimmunology, 362 (2022); 577788. https://doi.org/10.1016/j.jneuroim.2021.577788
Adamec, Ivan; Rogić, Dunja; Penz, Monika-Gabriele; Braun, Carola; Habek, Mario

Povezani objekti
COVID-19 | Virtualna zbirka

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Adamec, I., Rogić, D., Penz, M. G., Braun, C. i Habek, M. (2022). Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab. Journal of Neuroimmunology, 362.. doi: 10.1016/j.jneuroim.2021.577788

Adamec, Ivan, et al. "Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab." Journal of Neuroimmunology, vol. 362, 2022. https://doi.org/10.1016/j.jneuroim.2021.577788

Adamec, Ivan, Dunja Rogić, Monika Gabriele Penz, Carola Braun i Mario Habek. "Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab." Journal of Neuroimmunology 362 (2022). https://doi.org/10.1016/j.jneuroim.2021.577788

Adamec, I., et al. (2022) 'Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab', Journal of Neuroimmunology, 362. doi: 10.1016/j.jneuroim.2021.577788

Adamec I, Rogić D, Penz MG, Braun C, Habek M. Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab. Journal of Neuroimmunology [Internet]. 15.01.2022. [pristupljeno 05.11.2024.];362. doi: 10.1016/j.jneuroim.2021.577788

I. Adamec, D. Rogić, M. G. Penz, C. Braun i M. Habek, "Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab", Journal of Neuroimmunology, vol. 362, Siječanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:570068. [Citirano: 05.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:570068
Podaci o radu
Naslov (engleski)Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
AutorIvan Adamec
AutorDunja Rogić
MBZ: 147641
AutorMonika-Gabriele Penz
AutorCarola Braun
AutorMario Habek
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA NEUROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Objectives: To report clinical outcome, development of humoral and T-cell mediated immunity in convalescent COVID-19 people with multiple sclerosis (pwMS) treated with ofatumumab in the ALITHIOS study from a single center. ----- Methods: Testing for SARS-Cov2 IgG antibodies was performed on two occasions with at least three months apart between the two testing. During the second antibody testing, interferon-γ ELISpot was used to assess cellular immunity. ----- Results: All four subjects had mild COVID-19 infection without any sequelae. In all subjects except subject 2, COVID-19 was confirmed with PCR. Subjects 1, 2 and 4 had normal levels of IgM and IgG without measurable counts of CD19 cells prior to COVID-19. Subject 3 administered the last dose of ofatumumab 24 days prior to COVID-19 symptoms, but had a gap of 28 weeks of ofatumumab application beforehand due to low IgM levels. Subject 4 received COVID-19 vaccinations before second testing, so second testing and T-cell immunity testing were not performed. Subjects who were CD19 depleted did not had measurable levels of SARS-Cov2 IgG antibodies. Subject 3 had first and second SARS-COV2 titer of 118 U/ml and > 250 U/ml, respectively. All three pwMS showed T cell immunity against SARS-CoV-2. Quotient of basal spots divided by interferon-γ secreting spot forming units were 4, 8 and 14.7 SI in subjects 1, 2 and 3, respectively (>3 considered reactive).
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Neuroimmunology
Brojčani podacivol. 362, 577788
p-ISSN0165-5728
e-ISSN1872-8421
DOIhttps://doi.org/10.1016/j.jneuroim.2021.577788
URN:NBNurn:nbn:hr:105:570068
Datum objave publikacije2022-01-15
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S0165572821003155
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-03 08:22:46